Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Selective Bladder Preservation After Neoadjuvant Zanidatamab Combined With Tislelizumab and Chemotherapy in Patients With HER2-Positive Muscle-Invasive Bladder Cancer: A Multicenter Study

NCT07296705 is registered in ClinicalTrials.gov with Fujian Medical University Union Hospital as lead sponsor.

NCT NCT07296705
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07296705 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Selective Bladder Preservation After Neoadjuvant Zanidatamab Combined With Tislelizumab and Chemotherapy in Patients With HER2-Positive Muscle-Invasive Bladder Cancer: A Multicenter Study
Lead sponsor
Fujian Medical University Union Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
October 25, 2025
Completion date
December 31, 2029
Enrollment
25 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

muscle invasive bladder cancer (mibc)